CD34 and acute myeloid leukemia: Due to limitations in the efficiency of gene knockdown, either CRISPR/Cas9 or shRNA, in AML KG-1 cells, which are the early myeloblasts that are notoriously difficult to transfect similarly to CD34+ HSPCs, experiments were performed in AML HL-60 cells, which are more mature.